

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:

COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450,

ON 15 December 2004

NAME OF PERSON MAILING DOCUMENT

DATE

Attorney Docket No. P51032

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Jacques Briand

15 December 2004

Serial No.:

10/070,128

Group Art Unit No.: 1639

Filed:

27 February 2002

Examiner:

Mark Lance Shibuya

For:

Method of Using One-Dimensional and Multi-Dimensional Nuclear

Magnetic Resonance to Identify Compounds that Interact with Target

Biomolecules

Commissioner for Patents P.O. Box 1450 Alexandria VA, 22313-1450

Filing of an Information Disclosure Statement under 37 C.F.R. §1.97(c) and Certification under 37 C.F.R. §1.97(e)(1) or (e)(2)

Information Disclosure Statement. The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. Copies of each are enclosed, except for those references already part of the filewrapper. This statement is being filed with the required Certification and without any fee, in accordance with the provisions of 37 C.F.R. §1.97(c)(1) and (2), i.e., before a Final Action under 37 CFR §1.113 or a Notice of Allowance under 37 CFR §1.311.

ifas .

Serial No.: 10/070,128 Group Art Unit No.: 1639

<u>Statement of Certification</u>. The undersigned hereby certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Respectfully submitted,

Edward R. Gimmi Attorney for Applicants Registration No. 38,891

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-4478
Facsimile (610) 270-5090
N:\text{VERG\APPS\P51032\US National\UDS Letter 2.doc}

E.						SI	neet_l_c	of 1.
U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				ATTY. DOCKET NO. P51032		SERIAL NO. 10/070,128		
				APPLICANT Jacques Briand				
				FILING DATE 27 February 2002		GROUP 1639		
			U.S. PATEN	T DOCUMENTS				
Examiner Initial	Document Number	Date		Name	Class	Subclass		Date opriate
				0				
								
		FO	REIGN PAT	ENT DOCUMENTS		l		
	Document Number	Date		Country	Class	Subclass	<u>Trans</u> Yes	<u>lation</u> No
	OTHER DC	CUMENTS (I Includina A	uthor, Title, Date, Per	tinent Paaes.	Etc.)		1
	Hajduk, et al., "NN	MR-Based D	iscovery of	Phosphotyrosine Ministry Letters, 9: 240	imetics that E	Bind to the Lo	CK SH2	,
	Hensmann, et al., '	'Phosphopep	otide bindin	g to the N-terminal S Protein Science, 3: 10	SH2 domain	of the p85α s	ubunit c	of PI
	1531-1534 (1996).		· ·	gands for Proteins: S				_
	517-606 (1994).			ferred Noe Methods,	" Progress in	NMR Spect	roscopy,	, 26:
	Copy of Partial EP	Search Rep	ort.					
				·				
EXAMINER				DATE CONSIDERED	l.			

·EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant. N:\ERG\APPS\P51032\US National\1449 from search report.doc